| 1 |
Fletcher C,Berman J,Corless C,et al.Diagnosis of gastrointestinal stromal tumors:a consensus approach.Int J Surg Pathol,2002,10(2):81-89.
|
| 2 |
Rubin BP,Singer S,Tsao C,et al.KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.Cancer Res,2001,61(22):8118-8121.
|
| 3 |
Gold JS,Dematteo RP.Combined surgical and molecular therapy:the gastrointestinal stromal tumor model.Ann Surg,2006,44(2):176-184.
|
| 4 |
DeMatteo RP,Antonescu CR,Chadaram V,et al.Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor(GIST)following complete resection:safety results from the U.S.Intergroup Phase II trial ACOSOG Z9000.J Clin Oncol,2005,23(suppl 1):818.
|
| 5 |
DeMatteo R,Owzar K,Maki R, et al. Adjuvant imatinib mesylate increases recurrence free survival(RFS) in patients with completely resected localized primary gastrointestinal stromal tumor(GIST):North American Intergroup Phase III trial ACOSOG Z9001.2007 ASCO Annual Meeting.Abstract 10079.
|
| 6 |
Bonvalot S, Eldweny H, Pechoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors(GIST) in the imatinib era. Ann Surg Oncol,2006,13(12):1596-1603.
|
| 7 |
Heinrich MC,Corless CL,Duensing A,et al.PDGFRA activating mutations in gastrointestinal stromal tumors.Science,2003,299(5607):708-710.
|
| 8 |
Ando N,Goto H,Niwa Y,et al.The diagnosis of GIST with EUS guide fined needle aspiration with immunohistochemical analysis.Gastrointest Endosc,2002,55(1):37-43.
|
| 9 |
Choi H,Charnsangavej C,Faria SC,et al.CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment:a quantitative analysis correlated with FDG PET findings.AJR Am J Roentgenol,2004,183(6):1619-1628.
|
| 10 |
Andtbacka RH,Ng CS,Scaife CL,et al. Surgical resection of gasrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol, 2007, 14(1):14-24.
|
| 11 |
Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted sysemic therapy using kinase inhibitors.J Clin Oncol,2006,24(15):2325-2331.
|
| 12 |
Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.Ann Surg,2007,245(3):341-346.
|
| 13 |
DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor(GIST).Ann Surg,2007,245(3):347-352.
|
| 14 |
Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors(GIST)during therapy with imatinib mesylate.J Surg Oncol,2006,93(4):304-311.
|